BRCA1 germline pathogenic in metastatic PDAC after ≥16 weeks of platinum without progress...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRCA1-GERMLINE-PDAC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PDAC |
| Sources | SRC-CIVIC SRC-ESMO-PANCREATIC-2024 SRC-NCCN-PANCREATIC-2025 |
Actionability Facts
| Biomarker | BIO-BRCA1-BRCA2-GERMLINE |
|---|---|
| Variant | BRCA1 germline pathogenic |
| Disease | DIS-PDAC |
| ESCAT tier | IA |
| Recommended combinations | olaparib monotherapy maintenance after platinum-based 1L (FOLFIRINOX or gem-cis) |
| Evidence summary | BRCA1 germline pathogenic in metastatic PDAC after ≥16 weeks of platinum without progression: olaparib maintenance improves PFS (POLO, Golan 2019). No OS benefit demonstrated but durable PFS responders observed. ESCAT IA / OncoKB Level 1. |
Notes
Germline cascade testing mandatory. Platinum-based chemo (FOLFIRINOX preferred) is induction of choice in BRCA-mutated PDAC.
Used By
No reverse references found in the YAML corpus.